LifeCycle shares soar after low-dose organ rejection drug edges Prograf in Ph3 - FierceBiotech

Links shared publicly online about this topic.

  • 202
    total visits

LifeCycle shares soar after low-dose organ rejection drug edges Prograf in Ph3 - FierceBiotech

fiercebiotech.com —

In a head-to-head study with a market leading treatment designed to prevent kidney transplant rejection, Denmark's LifeCycle Pharma says that its once-daily experimental drug edged out Astellas's Read more...

View full resource at fiercebiotech.com

Tags: Kidney Health, Urinary System, Organ Transplant Rejection Medication, Kidney Transplant, Drug, Prograf

  • Share

Most Recently Shared on June 22, 2011 at 5:03 pm By:

thekidneygroup The Kidney Group

LifeCycle shares soar after low-dose organ rejection drug edges Prograf in Ph3. study. #kidney #transplant http://t.co/TDMG3hC

11 months ago...

Reply

Retweet

Favorite

Also Shared By:

FierceBiotech FierceBiotech

Advertisement